Endogenous PCSK9 may influence circulating CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/CD146^{neg} cells in patients with type 2 diabetes mellitus

Romina Tripaldi

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Paola Lanuti

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Paola Simeone

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Rossella Liani

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Giuseppina Bologna

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Sonia Ciotti

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Pasquale Simeone

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Augusto Di Castelnuovo

Mediterranea Cardiocentro, Napoli

Marco Marchisio

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Francesco Cipollone

Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi, Chieti

Francesca Santilli (✉ francesca.santilli@unich.it)

Research Article

Keywords: Endogenous PCSK9, Protease proprotein convertase subtilisin/kexin type 9, type 2 diabetes mellitus

Posted Date: November 20th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-109564/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Abstract

Protease proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of LDL cholesterol clearance and has been associated with cardiovascular risk. PCSK9 inhibitors increase in vivo circulating endothelial progenitor cells (EPCs), a subtype of immature cells involved in ongoing endothelial repair. We hypothesized that the effect of PCSK9 on vascular homeostasis may be mediated by EPCs in patients with or without type 2 diabetes mellitus (T2DM). Eighty-two patients (45 with, 37 without T2DM) at high cardiovascular risk were enrolled in this observational study. Statin treatment was associated with higher circulating levels of PCSK9 in patients with and without T2DM ($p < 0.001$ and $p = 0.036$) and with reduced CD45neg/CD34bright ($p = 0.016$) and CD45neg/CD34bright/CD146neg ($p = 0.040$) only among patients with T2DM. In the whole group of patients, statin treatment was the only independent predictor of low number of CD45neg/CD34bright ($\beta = -0.230$; $p = 0.038$, adjusted $R^2 = 0.041$). Among T2DM patients, PCSK9 circulating levels were inversely related and predicted both the number of CD45neg/CD34bright ($\beta = -0.438$; $p = 0.003$, adjusted $R^2 = 0.173$), and CD45neg/CD34bright/CD146neg ($\beta = -0.458$; $p = 0.002$, adjusted $R^2 = 0.191$) independently of age, gender, BMI and statin treatment. In high-risk T2DM patients, high endogenous levels of PCSK9 may have a detrimental effect on EPCs by reducing the endothelial repair and worsening the progression of atherothrombosis.

Introduction

Diabetes mellitus is associated with accelerated atherogenesis of the coronary, peripheral, and cerebrovascular districts and with a two-fold higher risk of atherothrombotic events, as compared to subjects without diabetes, despite extensive treatment with state-of-the art preventive therapies, including statins, anti-hypertensives, antiplatelet agents. There is urgent need to identify novel strategies tackling the residual risk of cardiovascular events.

Proprotein convertase subtilisin–kexin type 9 (PCSK9) is a secreted serine protease that binds to the extracellular domain of the low density lipoprotein (LDL) receptor and targets the LDL receptor to the lysosomal compartment for degradation¹. PCSK9 is secreted mainly by the liver and is found in 1 in every 500 LDL particles in the circulation². Mutations in PCSK9 have been associated with autosomal dominant hypercholesterolemia³.

Large trials have reported that PCSK9 inhibitors reduce LDL cholesterol and the risk of major cardiovascular (CV) events⁴, indicating PCSK9 as a novel therapeutic target, and establishing the indication to PCSK9 inhibitor treatment for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin⁵. A subsequent metanalysis revealed that the effects of PCSK9 inhibitors are comparable in patients with and without type 2 diabetes mellitus (T2DM)⁶.

Although the effect of PCSK9 inhibitors in cardiovascular prevention has been ascribed primarily to the strong LDL-cholesterol reducing action, additional mechanisms have been described such as the modulation of platelet function and blood coagulation⁷ and anti-atherosclerotic pleiotropic effects⁸. The

administration of anti-PCSK9 antibody inhibits markers of inflammation and atherosclerosis and interestingly, leads to an increase in circulating endothelial progenitor cells (EPCs) and angiogenic cells in a mouse model⁹. This mechanism may be particularly important since EPCs have been defined as “biomarkers” of endothelial function¹⁰, have a role in ongoing endothelial repair¹¹ and their reduction has been linked to CV outcomes¹². Indeed, after adjustment for relevant variables, increased levels of EPCs were associated with a reduced risk of death from CV causes, first major CV event, revascularization, and hospitalization¹³.

EPCs are damaged in disease. In patients with T2DM, EPCs exhibit impaired proliferation, adhesion, and incorporation into vascular structures¹⁴ and in patients at high risk for CV events EPCs show higher senescence. This may lead to EPCs depletion, thus impairing the repair of vessel walls and favouring the progression of CV disease¹⁵.

CD34 is a common marker for diverse progenitors, including hematopoietic stem and progenitor cells, vascular endothelial progenitors¹⁶, cardiomyocytes and smooth muscle cells¹⁷. Human CD34^{pos} cells are provided with vascular regenerative capacity and proangiogenic potential *in vivo*¹⁸, and their depletion is now considered a significant contributor to the impaired coronary endothelial dysfunction¹⁹ and altered cardiovascular homeostasis in diabetes. A useful marker to identify non hematopoietic stem and progenitor cells is the absence of the hematopoietic antigen CD45. The robust proliferative potential and endothelial colony forming capacity of CD45^{neg}/CD34^{pos} was confirmed *in vitro*²⁰. During the clinical onset of T2DM, a progressive reduction of CD34^{pos} progenitor cells has been observed²¹.

However, CD34 is also expressed on mature circulating endothelial cells (CECs), and thus additional and appropriate antigens are required to discriminate between CECs and EPCs. CD146 is a marker that may further help the characterization. CD146 is not expressed on early outgrowth EPCs while late outgrowth EPCs do express CD146²². While the phenotype of mature CECs (CD45^{neg}/CD34^{bright}/CD146^{pos}) is well established^{23,24}, the antigen pattern identifying EPCs has not been clarified yet. In any case, the circulating population of CD45^{neg}/CD34^{bright}/CD146^{neg} cells results enriched in the earlier EPCs^{22,25}. Another subpopulation of CD34^{pos} cells enriched in EPCs co-expresses CD309 or kinase insert domain receptor (KDR) or vascular endothelial growth factor receptor-2 (VEGFR2)²⁶.

We hypothesized that the effect of PCSK9 on vascular homeostasis may be mediated by EPCs. Thus, the aim of this study was to evaluate the relationship between circulating levels of PCSK9 and circulating EPCs as assessed by the number of CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/CD146^{neg} and CD45^{neg}/CD34^{bright}/CD309^{pos} and on CEC, as reflected by CD45^{neg}/CD34^{bright}/CD146^{pos}, and their mutual relationship, in patients at risk of CV disease, with or without T2DM.

Results

Baseline characteristics

Eighty-two patients were enrolled, 45 with and 37 without T2DM. Baseline characteristics of patients are reported in **Table 1**.

Table 1. Baseline characteristics.

Variable	No T2DM (n.37)	T2DM (n.45)	p-value ^a
Gender (male), n (%)	22 (59.4)	25 (55.5)	0.448
Age (years)	66 (58-75)	68 (65-71)	0.417
Weight (Kg)	77 (68-91)	81 (74-92)	0.323
BMI (kg/m ²)	28.2 (25.1-32.3)	30.1 (27.4-34.4)	0.079
Systolic BP (mmHg)	140.0 (127.5-158.0)	144.0 (135.5-150.5)	0.566
Diastolic BP (mmHg)	80.0 (70.5-87.0)	77.0 (70.0-83.0)	0.141
Hypertension, n (%)	33 (89.2)	39 (86.6)	0.500
Fasting plasma glucose (mmol/L)	5.2 (4.7-5.6)	6.7 (5.7-7.4)	<0.001
HbA1c (mmol/mol)	39.0 (34.0-42.0)	51.0 (43.0-56.0)	<0.001
Total cholesterol (mmol/L)	5.0 (4.0-5.6)	4.6 (3.9-5.2)	0.213
LDL cholesterol (mmol/L)	2.8 (2.1-3.4)	2.4 (2.0-3.0)	0.198
HDL cholesterol (mmol/L)	1.3 (1.1-1.5)	1.3 (1.1-1.4)	0.588
Triglycerides (mmol/L)	1.3 (1.0-1.7)	1.4 (1.1-1.9)	0.386
Creatinine (mmol/L)	70.4 (61.6-88.0)	70.4 (61.6-79.2)	0.654
eGFR (ml/min)	89.3 (72.0-100.0)	88.0 (78.0-95.5)	0.889
hs-C-reactive protein (nmol/L)	23.8 (7.6-46.7)	29.5 (10.5-63.8)	0.404
AST (U/L)	23.0 (20.5-28.5)	25.0 (20.0-31.0)	0.712
ALT (U/L)	27.0 (23.5-32.0)	30.0 (21.0-40.5)	0.393
Uric Acid (mmol/L)	351.0 (273.6-422.3)	333.1 (276.6-422.3)	0.456
CVD, n (%)	15 (40.5)	16 (35.5)	0.407
Diabetes Duration	-	6 (2.5-10)	-
Stable CAD, n (%)	1 (2.7)	5 (11.1)	0.152
Previous MI, or revascularization, n (%)	6 (16.2)	6 (13.6)	0.493
Previous TIA/stroke, o revascularization, n (%)	6 (16.2)	2 (4.4)	0.079
PAD, n (%)	0 (0)	3 (6.6)	0.160
Microvascular disease, n (%)	0 (0)	1 (2.2)	0.549
Retinopathy, n (%)	0 (0)	1 (2.2)	0.549
Chronic renal disease, n (%)	1 (2.7)	0 (0)	0.451
<i>Medications</i>			
Metformin, n (%)	1 (2.7)	27 (60)	<0.001
Sulfonylureas, n (%)	0 (0)	2 (4.4)	0.298
Glinides, n (%)	0 (0)	4 (8.8)	0.085
PPAR-gamma, n (%)	0 (0)	7 (15)	0.012
GLP1RA, n (%)	0 (0)	1 (2.2)	0.549
DPP-IVi, n (%)	0 (0)	1 (2.2)	0.549
Acarbose, n (%)	0 (0)	1 (2.2)	0.549
Insulin, n (%)	0 (0)	0 (0)	1.000
SGLT2i, n (%)	0 (0)	0 (0)	1.000
ACE-I, n (%)	11 (29.7)	16 (35.5)	0.375
ARBs, n (%)	11 (29.7)	10 (22.2)	0.301
Diuretics, n (%)	13 (35.1)	12 (26.6)	0.278
B-block, n (%)	19 (51.3)	13 (28.8)	0.032
CCA, n (%)	11 (29.7)	19 (42.2)	0.174
Statins, n (%)	11 (29.7)	25 (55.5)	0.016
Fibrates, n (%)	0 (0)	0 (0)	1.000
Ezetimibe, n (%)	0 (0)	3 (6.6)	0.160
Proton Pump Inhibitors, n (%)	17 (45.9)	18 (40)	0.375
ASA, n (%)	37 (100)	45 (100)	1.000

Abbreviations: BMI=body mass index, BP=blood pressure, CVD=cardiovascular disease, MI=myocardial infarction, TIA=transient ischemic attack, PAD=peripheral artery disease, ACE-I=ACE-inhibitors, ARBs=angiotensin receptor blockers, B-block=beta-blockers, CCA=calcium channel antagonists, ASA=acetylsalicylic acid. Data are median (25th - 75th percentile). ^aDetermined by Mann-Whitney or χ^2 test, as appropriate.

Patients were comparable for age ($p=0.417$), gender ($p=0.448$), BMI ($p=0.079$), prevalence of hypertension ($p=0.500$), CVD ($p=0.407$) and C-reactive protein ($p=0.404$).

Patients with T2DM were on statin treatment more frequently than patients without T2DM ($p=0.016$), while levels of total cholesterol ($p=0.213$), HDL ($p=0.588$), and triglycerides ($p=0.386$) were comparable.

As expected, patients were significantly different for fasting plasma glucose ($p<0.001$), HbA1c ($p<0.001$) and diabetes specific treatment such as metformin ($p<0.001$) and PPAR-gamma agonists ($p=0.012$). Notably, median HbA1c in T2DM patients was 6.8% (51.0 mmol/mol), reflecting good glycemic control in the group of patients with diabetes included in the study.

Repeatability of the outcome measurement

To verify the intra-subject reproducibility of the main outcome measured, we re-assessed EPC number after 24 hours in 9 out of 82 patients analyzed. We found no significant difference ($p=0.573$) between the two consecutive days measurements (data not shown).

Effect of T2DM and statin therapy

In patients with T2DM, as compared with patients without T2DM, we observed a trend toward higher levels of plasma PCSK9 ($p=0.092$) and lower number of CD45^{neg}/CD34^{bright} ($p=0.072$), CD45^{neg}/CD34^{bright}/CD146^{neg} ($p=0.051$) and CD45^{neg}/CD34^{bright}/CD309^{pos} ($p=0.072$) although these trends did not achieve statistical significance. The number of CD45^{neg}/CD34^{bright}/CD146^{pos} was comparable ($p=0.754$) (**Fig. 1**).

Thirty-six patients were on statin treatment, 25 with and 11 without T2DM. Patients on statin treatment had a higher prevalence of diabetes, previous myocardial infarction (MI), lower cholesterol and higher transaminase levels. Otherwise, their clinical characteristics were superimposable. Patients on statin treatment, both with and without T2DM, showed higher levels of PCSK9 as compared to their counterparts not on statins ($p<0.001$ and $p=0.036$ respectively) (**Fig. 2A**). Conversely, CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/CD146^{neg} were significantly lower in statin-treated patients than in patients not on statins, only among patients with T2DM ($p=0.016$ and $p=0.040$ respectively) (**Fig. 2B,C**). CD45^{neg}/CD34^{bright}/CD146^{pos} and CD45^{neg}/CD34^{bright}/CD309^{pos} were not affected by statin-treatment either in patients with or without T2DM (**Fig. 2D,E**).

Interestingly, among subjects not on statin therapy, no difference was detected in either PCSK9 levels or EPCs number between patients with vs. those without T2DM (**Fig. 2**), while significantly reduced

CD45^{neg}/CD34^{bright} (p=0.035) and CD45^{neg}/CD34^{bright}/CD146^{neg} (p=0.032) were observed in patients with diabetes vs. patients without diabetes only among statin-treated subjects (**Fig. 2B,C**).

Only among patients not on statins, we observed a positive correlation between PCSK9 and total cholesterol (Rho=0.369, p=0.012) and LDL cholesterol (Rho=0.470 p=0.001) (**Supplementary Fig.1**) but not with HDL or triglycerides (data not shown). Neither PCSK9 nor EPC number were related to fasting plasma glucose or HbA1c (data not shown).

PCSK9 and EPCs

In the whole group, PCSK9 correlated inversely with both CD45^{neg}/CD34^{bright} (Rho=-0.265, p=0.016) and CD45^{neg}/CD34^{bright}/CD146^{neg} (Rho=-0.246, p=0.026) (**Fig. 3A,D**). In patients with T2DM, PCSK9 correlated inversely with both CD45^{neg}/CD34^{bright} (Rho=-0.409, p=0.006) and CD45^{neg}/CD34^{bright}/CD146^{neg} (Rho=-0.448, p=0.002) (**Fig. 3C,F**), while such correlation was not observed in patients without T2DM (**Fig. 3B,E**). None of the other EPC phenotypes explored appeared to be correlated with PCSK9 circulating levels (**Supplementary Fig. 2**).

Since we have observed that statins affect both PCSK9 levels and CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/CD146^{neg}, we made a sub-analysis as a function of statin treatment. Interestingly, when dividing patients according to statin treatment, we found that the inverse correlations between PCSK9 levels and CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/CD146^{neg} remained only in patients with diabetes on statin treatment (Rho=-0.454, p=0.022 and Rho=-0.553, p=0.004 respectively) (**Fig. 4**).

Effect of previous myocardial infarction (MI)

Interestingly, patients with a previous MI (n=12) showed significantly higher levels of plasma PCSK9 (p=0.007), and significantly lower number of CD45^{neg}/CD34^{bright}/CD146^{neg} (p=0.031). Again, in patients with a previous MI, the prevalence of ongoing statin treatment was higher than in subjects without a history of previous MI (75% vs. 38%, p=0.025). The other phenotypes were comparable among patients with and without a previous MI (**Supplementary Fig. 3**).

Multivariate analyses

Multiple regression analyses performed on all patients, with different EPC phenotypes as the dependent variables, showed that statin treatment was the only independent predictor of the number of CD45^{neg}/CD34^{bright} (β =-0.230; t-value=-2.113; p=0.038) (adjusted R²=0.041, p=0.038). Multiple regression analyses on T2DM patients showed that PCSK9 circulating levels predicted both the number of CD45^{neg}/CD34^{bright} (β =-0.438; t-value, -3.199; p=0.003) (adjusted R²=0.173, p=0.003), and CD45^{neg}/CD34^{bright}/CD146^{neg} (β =-0.458; t-value, -3.376; p=0.002) (adjusted R²=0.191, p=0.002) independently of age, gender, BMI and statin treatment.

Discussion

In this cross-sectional study, we evaluated and compared the circulating levels of PCSK9, the number of several EPC phenotypes and their mutual relationship between patients with T2DM and without T2DM, otherwise comparable for most of the clinical characteristics. The main findings of our study are: 1. Statin treatment is associated with higher circulating levels of PCSK9 in both groups, and with reduced EPC number only among patients with T2DM; 2. PCSK9 and EPC number are comparable between patients with vs. without T2DM, when considering subjects not on statins. In contrast, among statin-treated patients, both EPC phenotypes evaluated are reduced in patients with T2DM vs. patients without T2DM. 3. Only in the group of T2DM patients, higher circulating PCSK9 is associated with reduced number of EPC. This inverse correlation is not observed in patients without T2DM or in the subgroup of patients not on statins, suggesting that in subjects with diabetes and in particular in statin-treated subjects, enhanced circulating PCSK9 may impair EPC number, reflecting cardiovascular homeostasis and regenerative capacity.

In our patients we observed higher levels of PCSK9 in patients treated with statins, both with and without T2DM. This is in line with the observation that statins can directly upregulate the expression of PCSK9^{27,28}. The observed trend toward higher circulating PCSK9 levels in T2DM patients is likely to be driven by the higher prevalence of statin treatment among T2DM (56% vs. 30%), rather than by an influence of glucose metabolism on PCSK9. While this influence is controversial in the literature²⁹, lack of correlation between fasting plasma glucose or HbA1c and PCSK9 does not support this hypothesis, at least in our cohort.

Additionally, only in patients not in treatment with statins, we found a direct correlation between PCSK9 levels and total cholesterol and LDL. It is known that statin therapy increasing PCSK9 levels and reducing cholesterol levels disrupt their direct correlation³⁰.

The effect of statins on EPCs is not well characterized, due to considerable heterogeneity in patient population, statin regimens and markers used for EPCs characterization in the diverse studies. Several studies reported a significant increase in EPCs following statin regimen³¹ while in patients with chronic coronary artery disease (CAD) statin-treated patients showed significantly reduced absolute and relative EPCs counts if compared to matched controls. Additionally, length of statin treatment seems to be an additional variable since in a prospective analysis, initiation of statin therapy significantly diminished the number of EPCs after 3 but not after 1 month³², suggesting EPC impairment with chronic statin use. Consistently, a short-term statin discontinuation increases EPCs in T2DM patients³³ The observation that statin treatment is associated with reduced number of CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/146^{neg} only among patients with T2DM, suggests that an interaction exists between diabetes and statins.

Interestingly, among the 12 patients with previous MI, PCSK9 and early EPC (CD45^{neg}/CD34^{bright}/146^{neg}) are higher and lower, respectively, as compared to patients without previous MI. Again, these differences

may be largely attributed to the higher prevalence of statin treatment among those with a history of previous MI (75% vs. 38%). However, our results are in line with previous observations of Laugsand reporting a 47% higher MI risk in patients in the highest quartile of circulating PCSK9³⁴. Consistently, a meta-analysis of 35 randomized controlled trials found that therapy with PCSK9 inhibitors was associated with a lower rate of MI (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; $p < 0.001$)³⁵. Likewise, EPCs reduction in patients with a previous MI may be a biomarker of endothelial damage and reflect EPC exhaustion, since EPC can migrate to the foci of ischemia to promote the repair of the injured organs³⁶. In our cohort, we did not observe any differences in CD45^{neg}/CD34^{bright} in patients with vs without a previous MI. However, this phenotype includes both EPCs and CECs, the latter characterized as CD45^{neg}/CD34^{bright}/CD146^{pos}²³. Indeed, after excluding the CECs, the remaining CD45^{neg}/CD34^{bright}/146^{neg} cells, reflecting early outgrowth EPCs²², are depleted in patients with a previous MI.

We hypothesized that EPC impairment may be mediated, at least in part, by PCSK9. Notably, in patients with T2DM, considered as a whole and in those treated with statins, we found an inverse correlation between PCSK9 levels and both CD45^{neg}/CD34^{bright} and CD45^{neg}/CD34^{bright}/146^{neg}. The link between PCSK9 and EPCs has been previously observed. In a study published by Chao et al in patients with peripheral artery disease, high plasma levels of PCSK9 were associated with dysfunction in EPCs³⁷. However, in the same study this observation was not paralleled by a reduction in the number of EPCs, at least using the CD34^{pos}/KDR^{pos} phenotype. A direct effect of PCSK9 levels on EPCs has been observed in a mouse model in which the administration of anti-PCSK9 antibodies increased the number of circulating EPCs⁹. Our results add further information to expand this hypothesis in humans. Statin treatment further increases PCSK9. Notably, EPCs impairment is prominent in patients with the highest levels of PCSK9, namely T2DM patients on statin treatment. Our findings of a putative selective effect of PCSK9 on EPC number only in patients with diabetes may provide a mechanistic explanation for the results of the ODYSSEY OUTCOMES trial, a randomised, double-blind, placebo-controlled trial performed in patients on high-intensity statin-treatment, showing that the anti-PCSK9 antibody alirocumab produced about twice the absolute reduction in CV events among patients with diabetes as in those without diabetes³⁸.

Limitations include the small sample to test the hypothesis of an interaction between diabetes and statins on EPC number. However, this pilot study is hypothesis-generating for a previously unappreciated effect of statins, to be confirmed on adequately sized samples. Another limitation is cross-sectional nature of the study. An intervention study assessing the effect of statin treatment on plasma PCSK9 and EPC number in patients with and without diabetes would have yielded definitive evidence.

Strengths include balance between the groups in terms of clinical characteristics, despite lack of randomization, and the method used to assess EPCs. Indeed, polychromatic flow cytometry used to enumerate and characterize EPCs has a standardized, high sensitive, flexible, and able to quickly analyse thousands of events and multiple parameters at the same time^{23,24}.

In conclusion, we unravelled, in patients with T2DM in good glycemic control, already treated with the state-of-the-art strategies for CV prevention (100% on ASA, 55% on statins, 85% antihypertensives), an inverse correlation between circulating PCSK9 and EPC number, with those on statins showing the highest PCSK9 levels paralleled by the most impaired EPC number. The relatively small sample size and the cross-sectional nature of this study do not allow us to confirm the cause-and-effect relationship between plasma PCSK9 and EPC number, nor a direct influence of statins on this biochemical and cell derangement. However, these findings highlight a piece of the pathophysiology underlying the “residual risk” of high-risk patients optimally treated with current preventive strategies, and suggest that EPC impairment may be reverted by PCSK9 inhibitors, thus providing an interesting mechanistic explanation for the cardiovascular benefit of this class of drugs and a further indication for the patient with diabetes on top of statins.

Materials And Methods

Patients recruitment

Forty-five T2DM patients (25 male, median age 68 years), with or without vascular disease, were enrolled at the Diabetes Clinic of Chieti University Hospital. Moreover, we studied 37 patients (22 male, median age 66 years) without T2DM, comparable for demographic, anthropometric and clinical characteristics, with particular reference to cardiovascular risk factors and concurrent treatments, referred to our Clinic by general practitioners. Each subject signed written informed consent to participate, and the Protocol was approved by the Ethics Committee of the University of Chieti (Prot.1129 18.07.2013).

T2DM diagnosis was made according to the ADA criteria (fasting plasma glucose ≥ 126 mg/dL or 2-h plasma glucose ≥ 200 mg/dL during OGTT or HbA1c ≥ 6.5 or a random plasma glucose ≥ 200 mg/dL)³⁹. All the patients were in treatment with low-dose aspirin (100 mg/die) for cardiovascular prevention. Exclusion criteria were: uncontrolled hypertension, uncontrolled dyslipidemia, significant comorbidities such as kidney or liver disease, pregnancy or lactation, chronic inflammation, cigarette smoking; clinically significant cardiac and/or pulmonary insufficiency; history of malignant neoplasms (diagnosed and treated within the past 5 years); history of malabsorption; regular (daily) alcohol consumption; regular (i.e., more than 3 days per week) non-steroidal anti-inflammatory drug intake. Type 1 diabetes was excluded by islet autoantibodies evaluation (anti-glutamic acid decarboxylase, islet cell cytoplasmic, and IA-2 antibodies), in the presence of any of the following: family history of type 1 diabetes, age lower than 40 years, lean phenotype, early requirement for insulin therapy. No patient was diagnosed as having MODY (Maturity Onset Diabetes of the Young).

This study was performed under the Good Clinical Practice regulations (Good Clinical Practice for Trial on Medicinal Product-CPMP/European Commission -July 1990; Decreto Ministeriale 27.4.1992-Ministero della Sanità) and the Declaration of Helsinki (Hong Kong 1989). By signing the protocol, the participants in the study committed to adhere to local legal requirements.

PCSK9 levels.

Since PCSK9 has a diurnal rhythm⁴⁰, all samples were collected at 8 a.m. after an overnight fasting. Blood collected into EDTA containing vacuum tubes (vacutainer, Becton Dickinson) was centrifuged at 1200 x g for 10 minutes at RT to separate plasma. Plasma was aliquoted in small volumes and frozen at -80°C. PCSK9 levels were measured with commercial enzyme-linked immunosorbent assays (ELISA) kit (#DPC900, R&D) according to the Manufacturer's instructions. Within-assay and between-assay coefficient of variations were below 7%.

Circulating endothelial cells.

The analysis of circulating endothelial cells was carried out by ptychometric flow cytometry on peripheral blood samples as already reported²⁴. Briefly, 20×10^6 leukocytes/sample underwent an erythrocyte-lysis step (45mL of Pharm Lyse solution - BD Biosciences - for 15 minutes at RT, under agitation) and then centrifuged (400 g, 10 min, room temperature). Once washed (2 mL of Stain Buffer, BD Biosciences), samples were centrifuged and stained using 1 μ M Syto16 (Thermo Fisher Scientific, Eisai, Medipost - US) and a lyophilized cocktail of reagents (BD Biosciences; cat. 623920)²⁴. Samples were incubated in the dark for 30 minutes at 4 °C, washed, centrifuged, re-suspended in 1.5mL of FACSFlow (BD Biosciences), and finally $2-4 \times 10^6$ events/sample with lymph-monocyte were acquired by flow cytometry (FACSCanto, FACSaria, BD Biosciences). A threshold combination was used on Forward Scatter (FSC) and Fluorescein isothiocyanate (FITC-Syto16) channels. Compensations were calculated using CompBeads (BD Biosciences) and single stained fluorescent cells. Carryover between samples was prevented by appropriate instrument cleaning at the end of each sample acquisition. $CD45^{neg}/CD34^{bright}$, $CD45^{neg}/CD34^{bright}/CD146^{neg}$, $CD45^{neg}/CD34^{bright}/CD146^{pos}$ and $CD45^{neg}/CD34^{bright}/CD309^{pos}$ phenotypes were analysed. Briefly, events displaying the typical lymph-monocyte morphology were first selected in a forward scatter (FSC) versus side scatter (SSC) plot. Next, dead cells were excluded on the basis of their positivity to 7-AAD and nucleated events (DNApos) were gated. The aforementioned three gates were intersected and cells resulting from this logical combination, characterized by lymph-monocyte morphological features, alive and nucleated, were then analysed for their phenotypes. Only non-hematopoietic $CD45^{neg}$ cells were further analysed. The whole $CD34^{positive}$ cell compartment displayed different levels of $CD34$ surface expression and two subpopulations were identified: $CD34^{positive}$ cells and a $CD34^{bright}$. $CD45^{neg}/CD34^{bright}$ cell population was then analysed for $CD146$ and $CD309$ expression, on $CD146/CD34$ and $CD309/CD34$ dot plots, respectively, and compared with the respective control tube dot plots, containing the isotype control of the anti- $CD146$ and anti- $CD309$ in combination with all the remaining reagents.

Statistical Analysis

The primary outcome measure is the number of $CD45^{neg}/CD34^{bright}$ cells. Our sample size has power=80% ($\alpha=0.05$) to detect a difference greater than 60% of the standard deviation in the primary

outcome between patients with diabetes and patients without diabetes, and power=80% ($\alpha=0.05$) to detect an interaction effect between diabetes status and statins use with an effect size >0.30 .

Comparisons of variables between groups were performed by X^2 tests or Mann-Whitney U tests. Spearman rank correlation test was used to assess relationships among variables. Stepwise multiple linear regression analysis was performed to assess variables independently associated with EPCs. Covariates included in the multiple regression models were selected on the basis of their significance on univariate analysis and their clinical relevance to the outcome of interest. They included diabetes, statin treatment, PCSK9 levels, age and gender, BMI.

Only 2-tailed probabilities were used for testing statistical significance, and $p<0.05$ was considered statistically significant. All calculations were carried out using SPSS (SPSS, Chicago, IL, USA). Sample size and power analysis have been conducted by using of GPower⁴¹.

Declarations

Author contributions: F.S. designed and set up the study. P.G.S. and F.S. were involved in patients enrolment. R.T., P.L., R.L., G.B., S.C., P.S. were involved in sample collection and/or analysis. R.T. and A.D.C. performed statistical analysis. F.S., R.T., P.G.S., P.L., M.M., F.C. were involved in data analysis and interpretation. F.S. and R.T. wrote the first draft of the paper. F.S., F.C., M.M. made a critical revision for important intellectual content. All the authors commented on this draft and the submitted version was approved by all authors. F.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding: This study was supported by grants from the Italian Ministry of University and Research (PRIN no. 2010JS3PMZ to F.S.) and the Italian Ministry of Health (COD WF GR 2011-02350450).

Conflicts of interest: The authors have nothing to disclose.

All authors have read the journal's authorship agreement and policy on disclosure of potential conflicts of interest.

References

1. Marais, D. A., Blom, D. J., Petrides, F., Gouëffic, Y. & Lambert, G. Proprotein convertase subtilisin/kexin type 9 inhibition. *Current Opinion in Lipidology* **23**, 511–517 (2012).
2. Shapiro, M. D., Tavori, H. & Fazio, S. PCSK9 from basic science discoveries to clinical trials. *Circulation Research* **122**, 1420–1438 (2018).
3. Abifadel, M. *et al.* Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat. Genet.* **34**, 154–156 (2003).

4. Sabatine, M. S. *et al.* Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.* **376**, 1713–1722 (2017).
5. Karr, S. Epidemiology and management of hyperlipidemia. *The American journal of managed care* **23**, S139–S148 (2017).
6. Monami, M., Sesti, G. & Mannucci, E. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. *Diabetes, Obes. Metab.* **21**, 903–908 (2019).
7. Paciullo, F., Momi, S. & Gresele, P. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. *Thrombosis and Haemostasis* **119**, 359–367 (2019).
8. Karagiannis, A. D. *et al.* Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. *Current Atherosclerosis Reports* **20**, 1–13 (2018).
9. Schuster, S. *et al.* Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. *Sci. Rep.*; doi:10.1038/s41598-019-47242-0 (2019).
10. Burger, D. & Touyz, R. M. Cellular biomarkers of endothelial health: Microparticles, endothelial progenitor cells, and circulating endothelial cells. *Journal of the American Society of Hypertension* **6**, 85–99 (2012).
11. Zampetaki, A., Kirton, J. P. & Xu, Q. Vascular repair by endothelial progenitor cells. *Cardiovascular Research*; doi:10.1093/cvr/cvn081 2008).
12. Schmidt-Lucke, C. *et al.* Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. *Circulation* **111**, 2981–7 (2005).
13. Werner, N. *et al.* Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. *N. Engl. J. Med.* **353**, 999–1007 (2005).
14. Tepper, O. M. *et al.* Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation*; doi:10.1161/01.CIR.0000039526.42991.93 (2002).
15. Hill, J. M. *et al.* *Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk.* *n engl j med* **348**, (2003).
16. Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S. & Hopkinson, A. Concise review: Evidence for CD34 as a common marker for diverse progenitors. *Stem Cells* **32**, 1380–1389 (2014).
17. Yeh, E. T. H. *et al.* Transdifferentiation of Human Peripheral Blood CD34+ Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo. *Circulation* **108**, 2070–2073 (2003).
18. Pozzoli, O. *et al.* Endothelial fate and angiogenic properties of human CD34+ progenitor cells in zebrafish. *Arterioscler. Thromb. Vasc. Biol.* **31**, 1589–97 (2011).

19. Boilson, B. A. *et al.* Circulating CD34+ cell subsets in patients with coronary endothelial dysfunction. *Nat. Clin. Pract. Cardiovasc. Med.* **5**, 489–496 (2008).
20. Case, J. *et al.* Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. *Exp. Hematol.*; doi:10.1016/j.exphem.2007.04.002 (2007).
21. Fadini, G. P. *et al.* Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. *Diabetes Care* **33**, 1097–1102 (2010).
22. Shim, Y., Nam, M. H., Hyuk, S. W., Yoon, S. Y. & Song, J. M. Concurrent hypermulticolor monitoring of CD31, CD34, CD45 and CD146 endothelial progenitor cell markers for acute myocardial infarction. *Anal. Chim. Acta* **853**, 501–507 (2015).
23. Lanuti, P. *et al.* Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. *Cytom. Part A* **89**, 259–270 (2016).
24. Lanuti, P. *et al.* A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. *Sci. Rep.* **8**, (2018).
25. Martin-Padura, I. *et al.* The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34 + progenitors able to promote cancer progression. *Cancer Res.*; doi:10.1158/0008-5472.CAN-11-1739 (2012).
26. Fadini, G. P., Losordo, D. & Dimmeler, S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. *Circ. Res.* **110**, 624–37 (2012).
27. Dubuc, G. *et al.* Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.*; doi:10.1161/01.ATV.0000134621.14315.43 (2004).
28. Mayne, J. *et al.* Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. *Lipids Health Dis.*; doi:10.1186/1476-511X-7-22 (2008).
29. Guo, W. *et al.* Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population. *Lipids Health Dis.* **17**, (2018).
30. Welder, G. *et al.* High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. *J. Lipid Res.*; doi:10.1194/jlr.M008144 (2010).
31. Hibbert, B. *et al.* The effect of statins on circulating endothelial progenitor cells in humans: A systematic review. *J. Cardiovasc. Pharmacol.* **62**, 491–496 (2013).
32. Hristov, M. *et al.* Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. *Atherosclerosis* **192**, 413–420 (2007).
33. Fadini, G. P. *et al.* Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. *Vascul. Pharmacol.* **67**, 21–29 (2015).
34. Laugsand, L. E. *et al.* Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway. *JACC: Basic to Translational Science* **1**, 568–575 (2016).

35. Karatasakis, A. *et al.* Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. *Journal of the American Heart Association* **6**, (2017).
36. Wu, Y. *et al.* Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. *Circ. Res.* **99**, 315–22 (2006).
37. Chao, T. H., Chen, I. C., Li, Y. H., Lee, P. T. & Tseng, S. Y. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells. *J. Am. Heart Assoc.* **5**, (2016).
38. Ray, K. K. *et al.* Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol.* **7**, 618–628 (2019).
39. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes; doi:10.2337/dc20-S002 (2019).
40. Persson, L. *et al.* Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. *Arterioscler. Thromb. Vasc. Biol.*; doi:10.1161/ATVBAHA.110.214130 (2010).
41. Erdfelder, E., Faul, F., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. *Behav. Res. Methods*; doi:10.3758/BRM.41.4.1149 (2009).

Figures

Figure 1

Effect of T2DM. Levels of plasma PCSK9 (a) and number of CD45neg/CD34bright (b), CD45neg/CD34bright/CD146neg (c), CD45neg/CD34bright/CD146pos (d) and CD45neg/CD34bright/CD309pos (e) in patients with and without T2DM.

Figure 2

Effect of statin treatment. Levels of plasma PCSK9 (a) and number of CD45neg/CD34bright (b), CD45neg/CD34bright/CD146neg (c), CD45neg/CD34bright/CD146pos (d) and CD45neg/CD34bright/CD309pos (e) in statin-treated patients (STAT) and in patients not on statins (NO STAT) with and without T2DM.

Figure 3

Plasma PCSK9 and EPCs. Correlations between levels of plasma PCSK9 and number of CD45neg/CD34bright (top) and CD45neg/CD34bright/CD146neg (bottom) in patients considered as a whole (a,d) and in those without (b,e) and with T2DM (c,f).

Figure 4

Plasma PCSK9, EPCs and statin treatment. Correlations between levels of plasma PCSK9 and number of CD45neg/CD34bright (a-d) and CD45neg/CD34bright/CD146neg (e-h) in patients considered as a whole not on statins (A,E) and on statins (C,G) and in T2DM patients not on statins (b,f) and on statins (d,h).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementary16.11.2020.pdf](#)